Charles River Labs: Buy Rating Reiterated as 2026 Outlook Strengthens; $235 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.
Analyst Charles Rhyee of TD Cowen has reiterated a Buy rating on Charles River Labs, maintaining a price target of $235. The positive outlook for 2026 is supported by strong demand from biotechnology clients, particularly mid-sized firms, and a solid book-to-bill ratio. Rhyee projects earnings of $11.04 for 2026, with a significant margin expansion expected. His analysis suggests the stock could trade at 19x the 2027 adjusted EPS estimate of $12.41, indicating attractive upside potential. Evercore ISI also maintains a Buy rating with a $220 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments